Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133
Tweet
Share
E-mail
Get Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Join SI Premium – FREE
Citi analyst Mohit Bansal reiterated a Buy rating and $150.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).
- Analyst is buyer on weakness.
- Sees FV around $131 to $133 per share.
- Says while weakness is justified, there is still value in the equity.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $112.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- RBC Capital Starts Opus Genetics (IRD) at Outperform
- Deutsche Bank Starts DexCom (DXCM) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
